{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:52:11Z","timestamp":1781635931289,"version":"3.54.5"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To clarify the efficacy of the intravitreal injections of faricimab and the change in vascular morphology of retinal-retinal anastomosis (RRA) after treatment in patients with type 3 macular neovascularization (MNV).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed 20 consecutive eyes with treatment-naive type 3 MNV in 14 Japanese patients (mean age, 81.8 years) at different stages. All patients were treated with 3 or 4 consecutive monthly intravitreal injections of faricimab and then they were followed by a \u201ctreat and extend, then fix\u201d regimen in the maintenance phase over a 12-month follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The mean logarithm of the minimum angle of resolution best-corrected visual acuity (BCVA) levels improved significantly (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01) from 0.87 at baseline to 0.64 at 12 months. Optical coherence tomography angiography (OCTA) findings confirmed RRA in 16 (84.2%) of the 19 eyes, except for the eye with stage 1 at baseline, and 15 (93.8%) of the 16 eyes demonstrated the presence of vascular continuity at 12 months. No progression of retinal pigment epithelium (RPE) atrophy was observed in any of the 3 eyes with RPE atrophy at baseline, and newly developed RPE atrophy was seen in 4 (23.5%) of the 17 eyes without RPE atrophy at baseline. All 20 eyes had dry macula and showed no other complications at 12 months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Intravitreal faricimab injections significantly improved VA, achieved dry macula, and nearly normalized the vessels on the RRA in most patients with type 3 MNV during the 12-month study period.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40942-026-00812-7","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T12:17:30Z","timestamp":1770639450000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["One-year results of the intravitreal administration of faricimab in patients with na\u00efve type 3 macular neovascularization"],"prefix":"10.1186","volume":"12","author":[{"given":"Masaaki","family":"Saito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimihiro","family":"Imaizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"812_CR1","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/00006982-200110000-00003","volume":"21","author":"LA Yannuzzi","year":"2001","unstructured":"Yannuzzi LA, Negr\u00e3o S, Iida T, Carvalho C, Rodriguez-Coleman H, Slakter J, et al. Retinal angiomatous proliferation in age-related macular degeneration. Retina. 2001;21:416\u201334.","journal-title":"Retina"},{"key":"812_CR2","first-page":"592","volume-title":"Degeneration: age-related macular degeneration. The retinal atlas","author":"LA Yannuzzi","year":"2010","unstructured":"Yannuzzi LA. Degeneration: age-related macular degeneration. The retinal atlas. Philadelphia: Saunders; 2010. pp. 592\u2013602."},{"key":"812_CR3","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/S0161-6420(96)30389-8","volume":"103","author":"ME Hartnett","year":"1996","unstructured":"Hartnett ME, Weiter JJ, Staurenghi G, Elsner AE. Deep retinal vascular anomalous complexes in advanced age-related macular degeneration. Ophthalmology. 1996;103:2042\u201353.","journal-title":"Ophthalmology"},{"key":"812_CR4","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1001\/archopht.123.12.1644","volume":"123","author":"F Bottoni","year":"2005","unstructured":"Bottoni F, Massacesi A, Cigada M, Viola F, Musicco I, Staurenghi G. Treatment of retinal angiomatous proliferation in age-related macular degeneration: a series of 104 cases of retinal angiomatous proliferation. Arch Ophthalmol. 2005;123:1644\u201350.","journal-title":"Arch Ophthalmol"},{"key":"812_CR5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ajo.2007.03.047","volume":"144","author":"I Maruko","year":"2007","unstructured":"Maruko I, Iida T, Saito M, Nagayama D, Saito K. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol. 2007;144:15\u201322.","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"812_CR6","doi-asserted-by":"crossref","first-page":"e0261320","DOI":"10.1371\/journal.pone.0261320","volume":"16","author":"M Saito","year":"2021","unstructured":"Saito M, Iida T, Saito K, Kano M, Itagaki K, Maruko I, et al. Long-term characteristics of exudative age-related macular degeneration in Japanese patients. PLoS ONE. 2021;16(12):e0261320.","journal-title":"PLoS ONE"},{"key":"812_CR7","first-page":"1929","volume":"37","author":"A Kvanta","year":"1996","unstructured":"Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 1996;37:1929\u201334.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"812_CR8","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1136\/bjo.81.2.154","volume":"81","author":"M Kliffen","year":"1997","unstructured":"Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol. 1997;81:154\u201362.","journal-title":"Br J Ophthalmol"},{"key":"812_CR9","first-page":"1891","volume":"40","author":"H Oh","year":"1999","unstructured":"Oh H, Takagi H, Takagi C. The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1999;40:1891\u20138.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"812_CR10","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1001\/archopht.120.3.338","volume":"120","author":"MG Krzystolik","year":"2002","unstructured":"Krzystolik MG, Afshari MA, Adamis AP, Gaudreault J, Gragoudas ES, Michaud NA, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol. 2002;120:338\u201346.","journal-title":"Arch Ophthalmol"},{"key":"812_CR11","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"119","author":"DF Martin","year":"2012","unstructured":"Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, et al. Ranibizumab and bevacizumab for treatment of neovascular Age-related macular degeneration: Two-Year results. Ophthalmology. 2012;119:1388\u201398.","journal-title":"Ophthalmology"},{"key":"812_CR12","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. MARINA study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419\u201331.","journal-title":"N Engl J Med"},{"key":"812_CR13","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. ANCHOR study group Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432\u201344.","journal-title":"N Engl J Med"},{"key":"812_CR14","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. VIEW 1 and VIEW 2 study Groups. Intravitreal Aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537\u201348.","journal-title":"Ophthalmology"},{"key":"812_CR15","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al. HAWK and HARRIER study Investigators. HAWK and HARRIER: phase 3, Multicenter, Randomized, Double-Masked trials of Brolucizumab for neovascular Age-Related macular degeneration. Ophthalmology. 2020;127:72\u201384.","journal-title":"Ophthalmology"},{"key":"812_CR16","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1097\/IAE.0b013e3181bfbd46","volume":"29","author":"M Engelbert","year":"2009","unstructured":"Engelbert M, Zweifel SA, Freund KB. Treat and extend dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization\/retinal angiomatous proliferation. Retina. 2009;29:1424\u201331.","journal-title":"Retina"},{"key":"812_CR17","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1136\/bjo.2009.167627","volume":"94","author":"TS Hemeida","year":"2010","unstructured":"Hemeida TS, Keane PA, Dustin L, Sadda SR, Fawzi AA. Long-term visual and anatomical outcomes following anti-VEGF monotherapy for retinal angiomatous proliferation. Br J Ophthalmol. 2010;94:701\u20135.","journal-title":"Br J Ophthalmol"},{"key":"812_CR18","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/IAE.0b013e3182979e62","volume":"34","author":"M Gharbiya","year":"2014","unstructured":"Gharbiya M, Parisi F, Cruciani F, Bozzoni-Pantaleoni F, Pranno F, Abdolrahimzadeh S. Intravitreal anti-vascular endothelial growth factor for retinal angiomatous proliferation in treatment-naive eyes: Long-term functional and anatomical results using a modified PrONTO-style regimen. Retina. 2014;34:298\u2013305.","journal-title":"Retina"},{"key":"812_CR19","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1136\/bjophthalmol-2013-304251","volume":"98","author":"M Inoue","year":"2014","unstructured":"Inoue M, Arakawa A, Yamane S, Kadonosono K. Long-term results of intravitreal Ranibizumab for the treatment of retinal angiomatous proliferation and utility of an advanced RPE analysis performed using spectral-domain optical coherence tomography. Br J Ophthalmol. 2014;98:956\u201360.","journal-title":"Br J Ophthalmol"},{"key":"812_CR20","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1097\/IAE.0000000000000225","volume":"34","author":"JY Shin","year":"2014","unstructured":"Shin JY, Yu HG. Optical coherence tomography-based Ranibizumab monotherapy for retinal angiomatous proliferation in Korean patients. Retina. 2014;34:2359\u201366.","journal-title":"Retina"},{"key":"812_CR21","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1097\/IAE.0000000000001104","volume":"36","author":"H Matsumoto","year":"2016","unstructured":"Matsumoto H, Sato T, Morimoto M, Ito A, Akiyama H. Treatand-extend regimen with Aflibercept for retinal angiomatous proliferation. Retina. 2016;36:2282\u20139.","journal-title":"Retina"},{"key":"812_CR22","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1136\/bjophthalmol-2018-312944","volume":"103","author":"A Invernizzi","year":"2019","unstructured":"Invernizzi A, Teo K, Nguyen V, Daniell M, Squirrell D, Barthelmes D, et al. Type 3 neovascularisation (retinal angiomatous proliferation) treated with antivascular endothelial growth factor:real-world outcomes at 24 months. Br J Ophthalmol. 2019;103:1337\u201341.","journal-title":"Br J Ophthalmol"},{"key":"812_CR23","doi-asserted-by":"crossref","first-page":"1141077","DOI":"10.3389\/fphar.2023.1141077","volume":"14","author":"M Fallico","year":"2023","unstructured":"Fallico M, Macchi I, Maugeri A, Favara G, Barchitta M, Magnano San Lio R, et al. Anti-vascular endothelial growth factor monotherapy or combined with verteporfin photodynamic therapy for retinal angiomatous proliferation: a systematic review with meta-analysis. Front Pharmacol. 2023;14:1141077.","journal-title":"Front Pharmacol"},{"key":"812_CR24","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1097\/IAE.0000000000004571","volume":"45","author":"JH Kim","year":"2025","unstructured":"Kim JH, Kim Y, Park SM, Cho HJ. Outcomes of Treat-and-Extend using Aflibercept in type 3 macular neovascularization: A prospective clinical trial. Retina. 2025;45:2018\u201326.","journal-title":"Retina"},{"key":"812_CR25","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/IAE.0b013e3181fe54c7","volume":"31","author":"VA McBain","year":"2011","unstructured":"McBain VA, Kumari R, Townend J, Lois N. Geographic atrophy in retinal angiomatous proliferation. Retina. 2011;31:1043\u201352.","journal-title":"Retina"},{"key":"812_CR26","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.ophtha.2013.12.034","volume":"121","author":"RP Finger","year":"2014","unstructured":"Finger RP, Wu Z, Luu CD, Kearney F, Ayton LN, Lucci LM, et al. Reticular pseudodrusen: a risk factor for geographic atrophy in fellow eyes of individuals with unilateral choroidal neovascularization. Ophthalmology. 2014;121:1252\u20136.","journal-title":"Ophthalmology"},{"key":"812_CR27","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ajo.2014.10.035","volume":"159","author":"HJ Cho","year":"2015","unstructured":"Cho HJ, Yoo SG, Kim HS, Kim JH, Kim CG, Lee TG, et al. Risk factors for geographic atrophy after intravitreal Ranibizumab injections for retinal angiomatous proliferation. Am J Ophthalmol. 2015;159:285\u201392.","journal-title":"Am J Ophthalmol"},{"key":"812_CR28","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s10384-015-0417-x","volume":"60","author":"M Saito","year":"2016","unstructured":"Saito M, Iida T, Kano M, Itagaki K. Two-year results of combined intravitreal Ranibizumab and photodynamic therapy for retinal angiomatous proliferation. Jpn J Ophthalmol. 2016;60:42\u201350.","journal-title":"Jpn J Ophthalmol"},{"key":"812_CR29","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00006982-199515030-00001","volume":"15","author":"JJ Arnold","year":"1995","unstructured":"Arnold JJ, Sarks SH, Killingsworth MC, Sarks JP. Reticular pseudodrusen. A risk factor in age-related maculopathy. Retina. 1995;15:183\u201391.","journal-title":"Retina"},{"key":"812_CR30","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ophtha.2009.07.014","volume":"117","author":"SA Zweifel","year":"2010","unstructured":"Zweifel SA, Spaide RF, Curcio CA, Malek G, Imamura Y. Reticular Pseudodrusen are subretinal drusenoid deposits. Ophthalmology. 2010;117:303\u201312.","journal-title":"Ophthalmology"},{"key":"812_CR31","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ajo.2012.08.011","volume":"155","author":"N Ueda-Arakawa","year":"2013","unstructured":"Ueda-Arakawa N, Ooto S, Nakata I, Yamashiro K, Tsujikawa A, Oishi A, et al. Prevalence and genomic association of reticular Pseudodrusen in age-related macular degeneration. Am J Ophthalmol. 2013;155:260\u20139.","journal-title":"Am J Ophthalmol"},{"key":"812_CR32","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.ajo.2008.06.033","volume":"146","author":"M Saito","year":"2008","unstructured":"Saito M, Shiragami C, Shiraga F, Kano M, Iida T. Combined intravitreal bevacizumab and photodynamic therapy for retinal angiomatous proliferation. Am J Ophthalmol. 2008;146:935\u201341.","journal-title":"Am J Ophthalmol"},{"key":"812_CR33","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ajo.2009.09.016","volume":"149","author":"M Saito","year":"2010","unstructured":"Saito M, Shiragami C, Shiraga F, Nagayama D, Iida T. Comparison of intravitreal triamcinolone acetonide with photodynamic therapy and intravitreal bevacizumab with photodynamic therapy for retinal angiomatous proliferation. Am J Ophthalmol. 2010;149:472\u201381.","journal-title":"Am J Ophthalmol"},{"key":"812_CR34","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ajo.2011.08.038","volume":"153","author":"M Saito","year":"2012","unstructured":"Saito M, Iida T, Kano M. Combined intravitreal Ranibizumab and photodynamic therapy for retinal angiomatous proliferation. Am J Ophthalmol. 2012;153:504\u201314.","journal-title":"Am J Ophthalmol"},{"key":"812_CR35","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.2147\/OPTH.S36333","volume":"6","author":"M Saito","year":"2012","unstructured":"Saito M, Iida T, Kano M, Itagaki K. Angiographic results of retinal-Retinal anastomosis and retinal-Choroidal anastomosis after treatments in eyes with retinal angiomatous proliferation. Clin Ophthalmol. 2012;6:1385\u201391.","journal-title":"Clin Ophthalmol"},{"key":"812_CR36","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10384-012-0215-7","volume":"57","author":"M Saito","year":"2013","unstructured":"Saito M, Iida T, Kano M. Two-year results of combined intravitreal anti-VEGF agents and photodynamic therapy for retinal angiomatous proliferation. Jpn J Ophthalmol. 2013;57:211\u201320.","journal-title":"Jpn J Ophthalmol"},{"issue":"10326","key":"812_CR37","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","volume":"399","author":"CC Wykoff","year":"2022","unstructured":"Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, et al. YOSEMITE and RHINE Investigators. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022;399(10326):741\u201355.","journal-title":"Lancet"},{"key":"812_CR38","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1097\/IAE.0000000000000627","volume":"35","author":"KB Freund","year":"2015","unstructured":"Freund KB, Korobelnik JF, Devenyi R, Framme C, Galic J, Herbert E, et al. Treatand- extend regimens with anti-VEGF agents in retinal diseases: a literature review and consensus recommendations. Retina. 2015;35:1489\u2013506.","journal-title":"Retina"},{"key":"812_CR39","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s12325-020-01236-x","volume":"37","author":"M Ohji","year":"2020","unstructured":"Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y. ALTAIR Investigators. Efficacy and safety of intravitreal Aflibercept Treat-and-Extend regimens in exudative Age-Related macular degeneration: 52- and 96-Week findings from ALTAIR: A randomized controlled trial. Adv Ther. 2020;37:1173\u201387.","journal-title":"Adv Ther"},{"issue":"1","key":"812_CR40","doi-asserted-by":"crossref","first-page":"30699","DOI":"10.1038\/s41598-025-15194-3","volume":"15","author":"M Saito","year":"2025","unstructured":"Saito M, Imaizumi K. Two-year results of switching to intravitreal administration of faricimab in patients with aflibercept-refractory neovascular age-related macular degeneration. Sci Rep. 2025;15(1):30699.","journal-title":"Sci Rep"},{"issue":"12","key":"812_CR41","doi-asserted-by":"crossref","first-page":"e0243458","DOI":"10.1371\/journal.pone.0243458","volume":"15","author":"M Saito","year":"2020","unstructured":"Saito M, Itagaki K, Sekiryu T. Fundus autofluorescence of retinal angiomatous proliferation. PLoS ONE. 2020;15(12):e0243458.","journal-title":"PLoS ONE"},{"key":"812_CR42","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","volume":"120","author":"S Rofagha","year":"2013","unstructured":"Rofagha S, Bhisitkul RB, Boyer DS, SEVEN-UP Study Group, et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120:2292\u20139.","journal-title":"Ophthalmology"},{"key":"812_CR43","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1097\/IAE.0000000000000834","volume":"35","author":"A Miere","year":"2015","unstructured":"Miere A, Querques G, Semoun O, El Ameen A, Capuano V, Souied EH. Optical coherence tomography angiography in early type 3 neovascularization. Retina. 2015;35:2236\u201341.","journal-title":"Retina"},{"key":"812_CR44","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/00006982-200509000-00005","volume":"25","author":"NE Gross","year":"2005","unstructured":"Gross NE, Aizman A, Brucker A, Klancnik JM Jr., Yannuzzi LA. Nature and risk of neovascularization in the fellow eye of patients with unilateral retinal angiomatous proliferation. Retina. 2005;25:713\u20138.","journal-title":"Retina"},{"issue":"10","key":"812_CR45","doi-asserted-by":"crossref","first-page":"e0310097","DOI":"10.1371\/journal.pone.0310097","volume":"19","author":"WT Yoon","year":"2024","unstructured":"Yoon WT, Lee SJ, Jeong JH, Kim JH. Prediction of fellow eye neovascularization in type 3 macular neovascularization (Retinal angiomatous proliferation) using deep learning. PLoS ONE. 2024;19(10):e0310097.","journal-title":"PLoS ONE"},{"key":"812_CR46","doi-asserted-by":"crossref","first-page":"101727","DOI":"10.1016\/j.ajoc.2022.101727","volume":"28","author":"M Saito","year":"2022","unstructured":"Saito M, Kobori H, Nozuki N, Kogawa S, Kudo A. A case of intraocular inflammation after intravitreal Brolucizumab injection monitored by laser flare-cell photometer. Am J Ophthalmol Case Rep. 2022;28:101727.","journal-title":"Am J Ophthalmol Case Rep"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-026-00812-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-026-00812-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-026-00812-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:57:12Z","timestamp":1781632632000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40942-026-00812-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["812"],"URL":"https:\/\/doi.org\/10.1186\/s40942-026-00812-7","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"assertion":[{"value":"4 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the institutional review board\/ethics committee of Iwaki City Medical Center (No.R6-28) for data collection and analysis and was carried out in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written consent was obtained for all patients included in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}